Researchers will use a lipidomic biomarker test to select patients with a poor prognosis who may benefit from an investigational combination therapy.

TEL-AVIV, Israel and RALEIGH, N.C. - RedHill Biopharma Ltd. (NASDAQ: NASDAQ:RDHL), a specialty biopharmaceutical company with a market capitalization of $7.53 million, today announced the initiation ...

The 80-patient placebo-controlled randomized Phase 2 study will evaluate the efficacy of opaganib in combination with Bayer's darolutamide in men with metastatic castrate-resistant ...

In a video interview, William K. Oh, MD, director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital discusses the latest breakthroughs in advanced prostate cancer treatment.

In a video interview, William K. Oh, MD, director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital discusses the latest breakthroughs in advanced prostate cancer treatment.

These included genetic models such as androgen receptor knockout mice and chronic androgen exposure in females using dihydrotestosterone (DHT) implants. Subsequently, they analyzed DNA from ...

The study carried out by Dr Marta Moreno-Rodríguez in the UPV/EHU group showed that the neurotransmitter receptors in the ... study of this new therapeutic pathway. To this end, they are working ...

1Cellular Degradation Biology Center, College of Medicine, Seoul National University, Seoul, Republic of Korea. 2Department of Biomedical Sciences, College of Medicine, Seoul National University, ...

Université de Bourgogne, U1231 INSERM, CTM, Equipe DesCarTes, UFR Sciences de Santé, 7 Bd Jeanne d’Arc, 21078 Dijon Cedex, France ...

The pathway controls the production of heat ... between higher levels of heat shock proteins and more androgen receptor signaling, which drives the development and growth of prostate cancer.